ICICI PrUDENTIAL MF LAUNCHES A new fund offer
ICICI Prudential Pharma Healthcare and
Diagnostics (P.H.D) Fund
NFO OPENS 25TH
JUNE 2018 and closeson 9TH JULY 2018
“Turning
India’s improving health opportunities into wealth creation opportunities”
Highlights of the NFO:
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund
is an Open Ended Equity Scheme, which aims to generate long term capital
appreciation by investing into the entire spectrum of health-related sub
sectors
§ India
has one of the largest youth populations. However, with a senior citizen
population at ~16Cr, together with increasing life expectancy, demand for
healthcare is expected to increase significantly.
§ India
has established itself as a global manufacturing and research hub by
contributing ~10% of the world production volume, and 50% of its revenue comes
from its pharmaceutical exports
§ Currently,
at ~5% of GDP, the spending in India is much lower than other developed and
developing economies.
§ Valuations
are attractive and it’s a good long term opportunity for investments in pharmaceutical sector
Chennai, June 26, 2018:
ICICI Prudential MF has announced
the launch of ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund.
The scheme aims to capitalize on the long-term growth story of Indian
healthcare as a whole. Rising income levels, increased health awareness, improvement
in treatment technologies and penetration of health insurance has led to healthcare
being one of the fastest growing segments
in the country. In fact, India
has established itself as a global manufacturing and research hub, which
contributes around 10% to the world productive volume.
Sharing his views
about the fund, Mr. Nimesh Shah, MD & CEO, said, “India continues to remain an under-penetrated market in terms of
healthcare services and insurance. As such, non-discretionary spend coupled
with increasing awareness make the theme a structural story for long period of
time. Due to higher growth, the pharma sector has always traded at a premium relative to the market but the premium
has narrowed down significantly in last few years. The recent underperformance
of pharma stocks makes a strong case for investing now in this sector.”
 |
| Caption - From Left Mr. S Haresh, Regional Head -Sales & Retail Tamil Nadu & Kerala and Mr. Atul Patel Fund Manager, ICICI Prudential Funds. |
A renewed focus of the Government on providing healthcare
facilities has put the spotlight back on this sector. In fact, the Government
initiative, “Pharma Vision 2020” aims
to make India a global leader in manufacturing as it enjoys the cost-efficient technology with the production
cost around 40% lower than the western countries. The fund seeks to capitalize
on all these investment opportunities.
Key Attributes:
Plan: Regular and Direct
Option: Growth and dividend
Minimum application amount: Rs 5,000 and in multiples of one rupee thereafter
Benchmark index: S&P BSE Healthcare Index
Entry /Exit load: Nil/ upto 18 months: 1%, Nil thereafter
Fund manager: Ihab M Dalwai
For further information please contact:
Adil Bakhshi - 022-66470274, +91-9920010203 pr@icicipruamc.com
Mutual Fund investments are subject to market risks, read all scheme related documents carefully.
Disclaimer:
All figures and data given in the document are dated unless stated otherwise. In the preparation of the material contained in this document, the AMC has used information that is publicly available, including information developed in-house.
The sector(s)/stock(s) mentioned in this document do not constitute any recommendation of the same and ICICI Prudential Mutual Fund may or may not have any future position in these sector(s)/stock(s). Information gathered and material used in this document is believed to be from reliable sources.
The Fund however does not warrant the accuracy, reasonableness and/or completeness of any information. For data reference to any third party in this material no such party will assume any liability for the same. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice and carefully read the scheme information document. We have included statements in this document, which contain words, or phrases such as "will", "expect", "should", "believe" and similar expressions or variations of such expressions that are "forward looking statements".
Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with our expectations with respect to, but not limited to, exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on our services and / or investments, the monitory and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices, the performance of the financial markets in India and globally, changes in domestic and foreign laws, regulations and taxes and changes in competition in the industry.
All data/information used in the preparation of this material is dated and may or may not be relevant any time after the issuance of this material. The AMC takes no responsibility of updating any data/information in this material from time to time.
The AMC (including its affiliates), the Fund and any of its officers directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner.
The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material.
No comments:
Post a Comment